GT Biopharma logo

GT BiopharmaNASDAQ: GTBP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 March 2018

Next earnings report:

26 March 2025

Last dividends:

N/A

Next dividends:

N/A
$6.84 M
-95%vs. 3y high
14%vs. sector
-vs. 3y high
-vs. sector
-48%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:14:37 GMT
$3.06+$0.14(+4.79%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

GTBP Latest News

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
globenewswire.com26 September 2024 Sentiment: POSITIVE

SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma's Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY. Company management will also be participating in 1x1 meetings during the event.

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
globenewswire.com27 June 2024 Sentiment: POSITIVE

SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.

Why Is GT Biopharma (GTBP) Stock Up 143% Today?
investorplace.com20 May 2024 Sentiment: POSITIVE

GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of GTBP stock changing hands as of this writing.

Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research02 June 2023 Sentiment: POSITIVE

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

What type of business is GT Biopharma?

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

What sector is GT Biopharma in?

GT Biopharma is in the Healthcare sector

What industry is GT Biopharma in?

GT Biopharma is in the Biotechnology industry

What country is GT Biopharma from?

GT Biopharma is headquartered in United States

When did GT Biopharma go public?

GT Biopharma initial public offering (IPO) was on 27 March 2018

What is GT Biopharma website?

https://www.gtbiopharma.com

Is GT Biopharma in the S&P 500?

No, GT Biopharma is not included in the S&P 500 index

Is GT Biopharma in the NASDAQ 100?

No, GT Biopharma is not included in the NASDAQ 100 index

Is GT Biopharma in the Dow Jones?

No, GT Biopharma is not included in the Dow Jones index

When was GT Biopharma the previous earnings report?

No data

When does GT Biopharma earnings report?

The next expected earnings date for GT Biopharma is 26 March 2025